Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon3 and 5 bp deletion in exon3.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-KDM1B, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LSD2 also known as AOF1 is a lysine-specific demethylase enzyme with a mass of about 105 kDa. This protein mainly functions by removing methyl groups from lysine residues on histone proteins thereby affecting chromatin structure and gene expression. LSD2 is expressed in various tissues with high levels in the liver and brain. The enzyme plays a significant role in regulating gene activity influencing many biological processes.
Biological function summary
LSD2 impacts gene expression by altering the epigenetic state of chromatin. It is not part of a well-defined large multiprotein complex allowing LSD2 to directly interact with histones. Through its demethylase activity it modulates the transcriptional regulation impacting cellular differentiation and proliferation. This makes it an important factor in maintaining cellular homeostasis.
Pathways
LSD2 is involved in histone modification processes particularly through the demethylation of H3K4me1 and H3K4me2 marks. These changes are important in the regulation of gene expression patterns. LSD2 often interacts with the REST corepressor complex affecting the expression of genes involved in neural development and function. It plays a role in pathways related to cellular stress responses and metabolic regulation highlighting its importance in cellular adaptation mechanisms.
LSD2 has been implicated in cancer and neurological disorders. Alterations in its expression and activity are associated with certain types of cancers such as breast cancer where it affects tumor growth and progression by influencing gene expression patterns. In neurological contexts LSD2's dysregulation impacts neural circuitry and cognitive functions which can be linked to disorders like Alzheimer's disease. In these conditions LSD2 interacts with proteins such as SIRT1 influencing cellular processes that contribute to disease pathology.
